Secondaries Announced 12.5.17

IPO BOUTIQUE CLIENTS and IPO BOUTIQUE SECONDARY ALERTS CLIENTS received ALL this information to their inbox on a REAL TIME basis.

If having real-time alerts for secondary offerings would be an advantage to you, inquire about a subscription today!

Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis. For example, this is not to be interpreted as a Buy recommendation in the traditional sense of adding to your stock portfolio; this is a short term (usually one day or opening trade) time period.

Company: GW Pharmaceuticals
Symbol: GWPH
Price: Last Trade $119.41
Trade Date: 12/7
Shares: 1.9 million ($225m cash raise)
Underwriter(s) : Goldman Sachs, Morgan Stanley, BofA Merrill Lynch, Cowen
Description: They are a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform.
Rating = Subscription Needed

Company: Bill Barrett Corporation
Symbol: BBG
Price: Last Trade $5.72
Trade Date: 12/6
Shares: 21 million
Re-Offer Range: Subscription Needed
Underwriter(s) : J.P. Morgan
Description: Headquartered in Denver, Colorado, they develop oil and natural gas in the Rocky Mountain region of the United States.
Rating = Subscription Needed

Company: Viking Therapeutics, Inc.
Symbol: VKTX
Price: Last Trade $2.74
Trade Date: 12/6
Shares: 4.7 million
Re-Offer Range: Subscription Needed
Underwriter(s) : William Blair
Description: Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.
Rating = Subscription Needed

Company: Editas Medicine
Symbol: EDIT
Price: Last Trade $27.29
Trade Date: 12/6
Shares: 1.9 million ($50 million)
Re-Offer Range: Subscription Needed
Underwriter(s) : Morgan Stanley
Description: Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes.
Rating = Subscription Needed

Company: Attunity Ltd.
Symbol: ATTU
Price: Last Trade $7.23
Trade Date: 12/6
Shares: 3.33 million ($20m -$25m)
Re-Offer Range: Subscription Needed
Underwriter(s) : William Blair, Needham, Roth
Description: They are a provider of Big Data management software solutions that enable access, management, sharing and distribution of data across heterogeneous enterprise platforms, organizations and the cloud.
Rating = Subscription Needed

Company: Revance Therapeutics, Inc.
Symbol: RVNC
Price: Last Trade $34.75
Trade Date: 12/7
Shares: 5 million ($175 million cash raise)
Underwriter(s) : Goldman Sachs, Cowen
Description: Revance is a clinical-stage biotechnology company focused on the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications.
Rating = Subscription Needed

Company: Integer Holdings Corporation – Block
Symbol: ITGR
Price: Last Trade $46.40
Trade Date: 12/6
Shares: 0.9 million
Re-Offer Range: Subscription Needed
Underwriter(s) : Morgan Stanley
Description: Integer Holdings Corporation operates as a medical device outsource manufacturer worldwide.
Rating = Subscription Needed